Here’s what you should know:
1. Sucampo’s Amitiza is the company’s only marketed product to date. Mylan markets the product in Japan, while Takeda holds global marketing rights to Amitiza. Takeda is working on launching Amitiza globally.
2. Sucampo is attempting to earn FDA approval for adult and pediatric patients by the second half of 2017.
3. Zacks reports the pharmaceutical company is attempting to make several acquisitions, as well. Sucampo recently acquired R-Tech, adding Rescula to its market drug list. In acquiring R-Tech, Sucampo added service lines in gastroenterology, ophthalmology, autoimmune disease, inflammatory diseases and oncology.
4. Sucampo also added a late stage Niemann-Pick Disease treatment to its development pipeline.
More articles on gastroenterology:
AGA on Better Care Reconciliation Act: ‘Patient access to care in peril’
GI center to know: University Gastroenterology
Takeda’s CEO under pressure & more — 5 GI company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.